There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

Estrogen receptor‐alpha (ERα) is the target of endocrine therapies for the treatment of more
than 70% of ERα‐positive breast cancers. Selective estrogen receptor degraders (SERDs) …

Abstract Background: CDK4/6 inhibitors have become the standard for first-line treatment of
metastatic luminal breast cancer based on consistent data from several phase 3 trials …

Highlights•CDK 4/6 inhibitors with ET is the standard first option in the treatment of advanced
luminal breast cancer.•There is no predictive biomarker easily applicable in clinical practice …

In the era of precision medicine, monoclonal antibodies and small molecule inhibitors are
the mainstays of the biological therapy in patients with solid tumors. However, resistance to …